GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sequent Scientific Ltd (BOM:512529) » Definitions » ROE % Adjusted to Book Value

Sequent Scientific (BOM:512529) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Sequent Scientific ROE % Adjusted to Book Value?

Sequent Scientific's ROE % for the quarter that ended in Dec. 2024 was 2.02%. Sequent Scientific's PB Ratio for the quarter that ended in Dec. 2024 was N/A. Sequent Scientific's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was N/A.


Sequent Scientific ROE % Adjusted to Book Value Historical Data

The historical data trend for Sequent Scientific's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sequent Scientific ROE % Adjusted to Book Value Chart

Sequent Scientific Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.57 1.64 1.20 -6.73 -1.21

Sequent Scientific Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.13 - 0.18 -

Competitive Comparison of Sequent Scientific's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Sequent Scientific's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sequent Scientific's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sequent Scientific's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Sequent Scientific's ROE % Adjusted to Book Value falls into.


;
;

Sequent Scientific ROE % Adjusted to Book Value Calculation

Sequent Scientific's ROE % Adjusted to Book Value for the fiscal year that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-5.29% / 4.37
=-1.21%

Sequent Scientific's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=2.02% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sequent Scientific ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Sequent Scientific's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Sequent Scientific Business Description

Traded in Other Exchanges
Address
Plot No. E7, Road No. 22, 301, 3rd Floor, Dosti Pinnacle, Wagle Industrial Estate, Thane (West), Mumbai, MH, IND, 400 604
Sequent Scientific Ltd is a pharmaceutical company operating animal health and analytical services. It develops API products and formulations. The company's product portfolio includes products across various therapy classes such as antibiotics, anthelmintics, pain management, and nutrition. The company's geographical segment includes Europe, Asia, and Rest of the world. It generates maximum revenue from Europe.

Sequent Scientific Headlines

No Headlines